Alper ÇAĞLAYAN, Ziya AKBULUT, Ali Fuat ATMACA, Serkan ALTINOVA, Metin KILIÇ, Mevlana Derya BALBAY

Effects of neoadjuvant chemotherapy on pathological parameters and survival in patients undergoing radical cystectomy for muscle-invasive bladder cancer

Aim: To evaluate the effect of neoadjuvant chemotherapy on tumor pathology and patient survival in patients with muscle-invasive bladder cancer undergoing radical cystectomy. Neoadjuvant chemotherapy is believed to prevent micrometastasis and provide pathological downstaging. Materials and methods: Between June 2004 and March 2009, 74 patients with muscle-invasive bladder cancer were treated with radical cystectomy. Patients fit to receive chemotherapy were administered systemic chemotherapy of methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC); gemcitabine and cisplatin (GC); or carboplatin and gemcitabine (CG). Patients in Group 1 (n = 36) did not receive any chemotherapy, while the remaining 38 patients in Group 2 did so, before radical cystectomy. Patient characteristics, pathological staging, and survival analysis were compared statistically between groups. Results: The mean follow-up time was 16.12 ± 12.13 months. There was no significant difference between the groups regarding patient age, sex, preoperative clinical staging, lymph node invasion, comorbidity, type of urinary diversions done, postoperative early complications, progression-free survival (21.96 ± 3.5 and 23.44 ± 2.5 months; P = 0.275), and overall survival rates (25.76 ± 3.5 and 23.57 ± 2.4 months; P = 0.646). However, differences in pathological downstaging (pT3-pT4, 21.58% and 16.42% for groups 1 and 2, respectively; P < 0.001) and perioperative mortality (6 vs. 0 deaths in groups 1 and 2; respectively) were significant between groups. Conclusion: Neoadjuvant chemotherapy may result in pathological downstaging while having no effects on progression-free or overall survival rates.

Anahtar Kelimeler:

Key words: Bladder cancer, chemotherapy, cystectomy, neoadjuvant

Effects of neoadjuvant chemotherapy on pathological parameters and survival in patients undergoing radical cystectomy for muscle-invasive bladder cancer

Keywords:

Key words: Bladder cancer, chemotherapy, cystectomy, neoadjuvant,

PDF

___

Greenlee RT, Murray T, Bolden S, Wings PA. Cancer statistics. CA Cancer J Clin 2000; 50: 7.
Calabro F, Sternberg CN. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol 2009; 55: 348-58.
Wallace DM, Raghavan D, Kelly KA, Sandeman TF, Conn IG, Teriana N et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 1991; 67: 608-15.
Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or defi nitive radiation. Th e National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14: 2901-7.
Martinez-Pineiro JA, Gonzalez Martin M, Arocena F, Flores N, Roncero CR, Portillo JA et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 1995; 153: 964-73.
Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E. Five-year follow up at a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial. Th e Nordic Cooperative Bladder Cancer Study Group. J Urol 1996; 155: 1903-6.
Ghoneim MA, Abol-Enein H. Management of muscle-invasive bladder cancer. Nat Clin Pract Urol 2008; 5: 501-8.
Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF et al. Surgical factors infl uence bladder cancer outcome: a cooperative group report. J Clin Oncol 2004; 22: 2781-9.
McLaren DB. Neoadjuvant chemotherapy in transitional-cell carcinoma of the bladder. Clin Oncol 2005; 17: 503-7.
Black PC, Brown GA, Grossman HB, Dinney CP. Neoadjuvant chemotherapy for bladder cancer. World J Urol 2006; 24: 531- 42.
Sawhney R, Bourgeois D, Chaudhary UB. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a look ahead. Ann Oncol 2006; 17: 1360-9.
Kulkarni GS, Urbach DR, Austin PC, Laupacis A. Longer wait times increase overall mortality in patients with bladder cancer. J Urol 2009; 182: 1318-24.
Smaldone MC, Corcoran AT, Hayn M, Konety BR, Hrebinko RL Jr, Davies BJ. Estimating postoperative mortality and morbidity risk of radical cystectomy with continent diversion using predictor equations. J Urol 2009; 182: 2619-24.